Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Harley-Davidson Inc (HOG) vs Merck & Co., Inc. (MRK) Price & Performance

Harley-Davidson IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Harley-Davidson Inc vs Merck & Co., Inc. — how do they compare? Harley-Davidson Inc trades at $26.51 (market cap $2.72B), while Merck & Co., Inc. trades at $130.54 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 118.8× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.82%). Which is the better fit depends on your goals.

HOGMRK
Market Cap
$2.72B$323.00B
Sector
Consumer CyclicalHealth
52-Week High
$31.03$131.84
52-Week Low
$17.19$77.60
Enterprise Value
$3.13B$369.77B
Dividend Yield
2.82%2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Harley-Davidson Inc

Harley-Davidson (HOG) trades at $26.01, up 1.21% daily, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q2 2026 EPS of $0.75, beating estimates, and raised full-year guidance. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin at 4.78%. Valuation ratios appear attractive with a P/E of 14.45 and P/B of 0.87. Recent news highlights North American sales strength and a strategic shift to U.S. production.

The outlook is cautiously optimistic; earnings beat and raised guidance support upside, but declining revenue and margin pressures pose risks. Analyst consensus is mixed with a $26 price target. Key risks include competitive threats and raw material costs. The stock's valuation discount offers potential if turnaround efforts gain traction.

Merck & Co., Inc.

MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.

Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Harley-Davidson Inc

Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.

Read more on HOG

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK